Diseases /
Anaplastic Ependymoma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A WHO grade III malignant glioma of ependymal origin with accelerated growth and an unfavorable clinical outcome, particularly in children. It is characterized by high mitotic activity, often accompanied by microvascular proliferation and pseudo-palisading necrosis. (Adapted from WHO) [1]
Anaplastic ependymomas most frequently harbor alterations in RELA, C11orf95, CDKN2A, TP53, and ZFHX3 [2].
C11orf95-RELA Fusion, RELA Fusion, TP53 c.217-c.1178 Missense, TP53 Mutation, and TP53 Missense are the most common alterations in anaplastic ependymoma [2].
Clinical Trials
Significant Genes in Anaplastic Ependymoma
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.